Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

ABSTRACT: Key Points • DTI is strongly associated with adverse clinical factors and inferior survival outcomes in patients with newly diagnosed MCL.• DTI should be reported in all patients newly diagnosed with MCL enrolling in clinical trials; steps must be taken to avoid selection bias. Visual Abstract Abstract The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought to evaluate the impact of DTI on outcomes in MCL using 3 large datasets (1) the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource, (2) patients enrolled in the ALL Age Asthma Cohort/CALGB 50403, and (3) a multisitecohort of patients with MCL. Patients were a priori divided into 2 gro

SUBMITTER: Epperla N 

PROVIDER: S-EPMC10225877 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature